{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:27Z","timestamp":1792787307857,"version":"4.5.0"},"reference-count":34,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Humacyte, Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Trauma Surg Acute Care Open"],"accepted":{"date-parts":[[2025,10,5]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate the short-term clinical performance of Symvess (acellular tissue engineered vessel-tyod), formerly known as human acellular vessel, or HAV, compared with autologous vein for the treatment of extremity arterial injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Subjects treated with acellular tissue engineered vessel (ATEV) from two clinical trials were propensity score-matched on a 1:2 basis to PROspective Observational Vascular Injury Trial (PROOVIT) registry subjects with the same injured artery and treated with autologous vein. Matching characteristics included age, sex, trauma type (penetrating vs blunt), injury severity score, mangled extremity severity score, concomitant fracture, shunt use, and ischemia duration&gt;6\u2009hours. Incidence of outcomes (primary\/secondary patency, amputation, conduit infection, reintervention for thrombosis\/stenosis, pseudoaneurysm, and death) was assessed by a generalized linear model. Outcomes were assessed at Day 30 (ATEV group) or during initial hospitalization (autologous group).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ATEV subjects lacking suitable autologous vein (n=67) and PROOVIT subjects treated with autologous vein (n=134) suffered injuries to axillary, brachial, femoral, popliteal, and posterior tibial arteries. Subgroups were clinically similar; Injury Severity Score, Mangled Extremity Severity Score, and duration of follow-up (16 vs 30 days) were higher for the ATEV subgroup.<\/jats:p>\n                    <jats:p>Primary patency for the ATEV versus autologous group was 86.6% versus 91.8%, secondary patency: 91.0% versus 97.7%; amputation: 7.5% versus 8.2%; conduit infection: 1.5% versus 0%; reintervention for thrombosis or stenosis: 6.0% versus 8.2%; and death 4.5% versus 4.5%, respectively. No cases of pseudoaneurysm, true aneurysm, or significant differences between the ATEV and autologous groups for any outcome were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Short-term outcomes were similar between ATEV subjects without feasible autologous vein, and propensity score-matched autologous vein recipients from the PROOVIT registry. The ATEV may provide effective and safe revascularization in subjects with extremity arterial injury without feasible autologous vein.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of evidence<\/jats:title>\n                    <jats:p>Level 3, Therapeutic\/Care Management<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/tsaco-2025-001814","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:10:23Z","timestamp":1761736223000},"page":"e001814","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Short-term performance of Symvess (acellular tissue engineered vessel-tyod) compared to external control data for autologous vein in treatment of extremity arterial injury"],"prefix":"10.1136","volume":"10","author":[{"given":"Ravi R","family":"Rajani","sequence":"first","affiliation":[{"name":"Division of Vascular Surgery, Department of Surgery, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-5933","authenticated-orcid":false,"given":"Fulton F","family":"Velez","sequence":"additional","affiliation":[{"name":"Humacyte Inc, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Knight","sequence":"additional","affiliation":[{"name":"Fortrea Inc, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kauffman","sequence":"additional","affiliation":[{"name":"Fortrea Inc, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Pascarella","sequence":"additional","affiliation":[{"name":"Division of Vascular Surgery, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C","family":"Malone","sequence":"additional","affiliation":[{"name":"Strategic Therapeutics, LLC, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd E","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E","family":"Niklason","sequence":"additional","affiliation":[{"name":"Humacyte Inc, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2380-439X","authenticated-orcid":false,"given":"Shamik","family":"Parikh","sequence":"additional","affiliation":[{"name":"Humacyte Inc, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"2026010700454584000_10.4.e001814.1","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.avsg.2014.12.026","article-title":"A retrospective cohort comparison of expanded polytetrafluorethylene to autologous vein for vascular reconstruction in modern combat casualty care","volume":"29","author":"Watson","year":"2015","journal-title":"Ann Vasc Surg"},{"key":"2026010700454584000_10.4.e001814.2","unstructured":"Huber GH , Manna B . Vascular extremity trauma. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright 2024. StatPearls Publishing LLC, 2024."},{"key":"2026010700454584000_10.4.e001814.3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jvs.2024.03.438","article-title":"Current outcomes following upper and lower extremity arterial trauma from the National Trauma Data Bank","volume":"80","author":"Kim","year":"2024","journal-title":"J Vasc Surg"},{"key":"2026010700454584000_10.4.e001814.4","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1097\/TA.0000000000002967","article-title":"American Association for the Surgery of Trauma-World Society of Emergency Surgery guidelines on diagnosis and management of peripheral vascular injuries","volume":"89","author":"Kobayashi","year":"2020","journal-title":"J Trauma Acute Care Surg"},{"key":"2026010700454584000_10.4.e001814.5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.avsg.2019.05.017","article-title":"Comparison of Autologous Vein and Bovine Carotid Artery Graft as a Bypass Conduit in Arterial Trauma","volume":"61","author":"Reilly","year":"2019","journal-title":"Ann Vasc Surg"},{"key":"2026010700454584000_10.4.e001814.6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1089\/ten.teb.2015.0100","article-title":"The Tissue-Engineered Vascular Graft-Past, Present, and Future","volume":"22","author":"Pashneh-Tala","year":"2016","journal-title":"Tissue Eng Part B Rev"},{"key":"2026010700454584000_10.4.e001814.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.319984"},{"key":"2026010700454584000_10.4.e001814.8","first-page":"435","article-title":"Biomechanics and biocompatibility of the perfect conduit-can we build one?","volume":"2","author":"Byrom","year":"2013","journal-title":"Ann Cardiothorac Surg"},{"key":"2026010700454584000_10.4.e001814.9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau6934","article-title":"Bioengineered human acellular vessels recellularize and evolve into living blood vessels after human implantation","volume":"11","author":"Kirkton","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026010700454584000_10.4.e001814.10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.avsg.2022.03.037","article-title":"Preliminary Experience With the Human Acellular Vessel: A Descriptive Case Series Detailing Early Use of a Bioengineered Blood Vessel for Arterial Repair","volume":"87","author":"Lauria","year":"2022","journal-title":"Ann Vasc Surg"},{"key":"2026010700454584000_10.4.e001814.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100650","article-title":"Use of bioengineered human acellular vessels to treat traumatic injuries in the Ukraine-Russia conflict","volume":"29","author":"Sokolov","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026010700454584000_10.4.e001814.12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1001\/jamasurg.2022.1214","article-title":"The Human Acellular Vessel for Vascular Reconstruction or Bypass: A Novel Biologic Conduit for Vascular Bypass and Repair","volume":"157","author":"Lauria","year":"2022","journal-title":"JAMA Surg"},{"key":"2026010700454584000_10.4.e001814.13","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jvs.2019.11.056","article-title":"Arterial reconstruction with human bioengineered acellular blood vessels in patients with peripheral arterial disease","volume":"72","author":"Gutowski","year":"2020","journal-title":"J Vasc Surg"},{"key":"2026010700454584000_10.4.e001814.14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvscit.2023.101123","article-title":"The Human Acellular Vessel (HAV) as a vascular conduit for infrainguinal arterial bypass","volume":"9","author":"Farazdaghi","year":"2023","journal-title":"J Vasc Surg Cases Innov Tech"},{"key":"2026010700454584000_10.4.e001814.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvssci.2022.11.001","article-title":"Six-year outcomes of a phase II study of human-tissue engineered blood vessels for peripheral arterial bypass","volume":"4","author":"Gutowski","year":"2023","journal-title":"JVS Vasc Sci"},{"key":"2026010700454584000_10.4.e001814.16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jvs.2023.10.040","article-title":"Outcomes of lower extremity arterial bypass using the Human Acellular Vessel in patients with chronic limb-threatening ischemia","volume":"79","author":"Cifuentes","year":"2024","journal-title":"J Vasc Surg"},{"key":"2026010700454584000_10.4.e001814.17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/jamasurg.2024.4893","article-title":"Bioengineered Human Arteries for the Repair of Vascular Injuries","volume":"160","author":"Moore","year":"2025","journal-title":"JAMA Surg"},{"key":"2026010700454584000_10.4.e001814.18","unstructured":"Berdugo M , Nicholson G , Halbert R , et al . Prosthetic Vascular Grafts for Treatment of Acute Injuries: A Systematic Literature Review and Meta-Analysis. Manuscript In Submission 2025."},{"key":"2026010700454584000_10.4.e001814.19","unstructured":"Humacyte Inc . [Benchmarking REPORT (REP-MET-003). Clinical Outcomes of Human Acellular Vessel vs. Literature-based External Benchmarks for Arterial Repair of Extremity Vascular Trauma] data on file; 2024."},{"key":"2026010700454584000_10.4.e001814.20","doi-asserted-by":"crossref","unstructured":"DuBose JJ , Savage SA , Fabian TC , et al . The American Association for the Surgery of Trauma PROspective Observational Vascular Injury Treatment (PROOVIT) registry: multicenter data on modern vascular injury diagnosis, management, and outcomes. J Trauma Acute Care Surg 2015;78. doi:10.1097\/ta.0000000000000520","DOI":"10.1097\/01.ta.0000462355.64669.41"},{"key":"2026010700454584000_10.4.e001814.21","unstructured":"US national library of medicine . Humacyte human acellular vessel (hav) in patients with vascular trauma, clinicaltrials.gov identifier: nct03005418 ; 2024."},{"key":"2026010700454584000_10.4.e001814.22","unstructured":"Humacyte inc . Humacyte Completes Enrollment in Phase 2\/3 Trial of Human Acellular Vessel (HAV) for Vascular Trauma Repair; 2024."},{"key":"2026010700454584000_10.4.e001814.23","unstructured":"Humacyte Inc . Humacyte Announces Two Presentations at the VEITHsymposium of Positive Clinical Results of the Human Acellular Vessel (HAV) in the Treatment of Vascular Trauma; 2023."},{"key":"2026010700454584000_10.4.e001814.24","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezy167"},{"key":"2026010700454584000_10.4.e001814.25","doi-asserted-by":"publisher","DOI":"10.1037\/a0015914"},{"key":"2026010700454584000_10.4.e001814.26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1751-7176.2010.00264.x","article-title":"Comparison of statistical approaches to evaluate factors associated with metabolic syndrome","volume":"12","author":"Fekedulegn","year":"2010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026010700454584000_10.4.e001814.27","unstructured":"Sheskin DJ . Handbook of parametric and nonparametric statistical procedures. 5th edn. Chapman and Hall\/CRC, 2011."},{"key":"2026010700454584000_10.4.e001814.28","doi-asserted-by":"crossref","DOI":"10.1186\/s13017-016-0084-3","article-title":"Management of traumatic wounds in the Emergency Department: position paper from the Academy of Emergency Medicine and Care (AcEMC) and the World Society of Emergency Surgery (WSES)","volume":"11","author":"Prevaldi","year":"2016","journal-title":"World J Emerg Surg"},{"key":"2026010700454584000_10.4.e001814.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2005.01.010"},{"key":"2026010700454584000_10.4.e001814.30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/SLA.0000000000005560","article-title":"Impact of Ischemia Duration on Lower Limb Salvage in Combat Casualties","volume":"276","author":"Perkins","year":"2022","journal-title":"Ann Surg"},{"key":"2026010700454584000_10.4.e001814.31","unstructured":"Humacyte inc . Proovit analysis of arterial repair types data on file; 2024."},{"key":"2026010700454584000_10.4.e001814.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2006.04.054"},{"key":"2026010700454584000_10.4.e001814.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2014.05.049"},{"key":"2026010700454584000_10.4.e001814.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2018.01.066"}],"container-title":["Trauma Surgery &amp; Acute Care Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/tsaco-2025-001814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:46:27Z","timestamp":1767775587000},"score":1,"resource":{"primary":{"URL":"https:\/\/tsaco.bmj.com\/lookup\/doi\/10.1136\/tsaco-2025-001814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,29]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/tsaco-2025-001814"],"URL":"https:\/\/doi.org\/10.1136\/tsaco-2025-001814","relation":{},"ISSN":["2397-5776"],"issn-type":[{"value":"2397-5776","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}